The CESAR trial uses the combination of Kyprolis, Revlimid, and dexamethasone plus autologous stem-cell transplant to treat high-risk smoldering multiple myeloma. It applies:

• Precise mininal residual disease (MRD) testing using next-generation flow cytometry (NGF)
• Blood testing for routine monitoring